Protalix BioTherapeutics, Inc.
Protalix develops recombinant enzyme replacement therapies for rare diseases using plant cell-based expression.
6-KAug 18Latest SEC filing, period to Aug 18
Aug 12Latest story
August 2026
Sign inSign inProtalix develops recombinant enzyme replacement therapies for rare diseases using plant cell-based expression.